Capacity Expansion with Built-in Revenue Visibility Jubilant Ingrevia's agro-intermediate CDMO investment unlocks contracted revenue with predictable scaling. Material dispatch has commenced, enabling Q3/Q4 FY25 revenue recognition. While initial margins face ramp-up pressures (70-75% gross), EBITDA improves significantly post-70% utilization, targeting 15-25% margins in 2-3 quarters. The CDMO model provides client stickiness and operating leverage benefits. Key risks include ramp delays and agrochemical cyclicality. Net-positive trajectory expected FY26+, positioning stronger competitive standing in specialty chemicals.

Capacity Expansion with Built-in Revenue Visibility Jubilant Ingrevia's agro-intermediate CDMO investment unlocks contracted revenue with predictable scaling. Material dispatch has commenced, enabling Q3/Q4 FY25 revenue recognition. While initial margins face ramp-up pressures (70-75% gross), EBITDA improves significantly post-70% utilization, targeting 15-25% margins in 2-3 quarters. The CDMO model provides client stickiness and operating leverage benefits. Key risks include ramp delays and agrochemical cyclicality. Net-positive trajectory expected FY26+, positioning stronger competitive standing in specialty chemicals.

Capacity Expansion with Built-in Revenue Visibility Jubilant Ingrevia's agro-intermediate CDMO investment unlocks contracted revenue with predictable scaling. Material dispatch has commenced, enabling Q3/Q4 FY25 revenue recognition. While initial margins face ramp-up pressures (70-75% gross), EBITDA improves significantly post-70% utilization, targeting 15-25% margins in 2-3 quarters. The CDMO model provides client stickiness and operating leverage benefits. Key risks include ramp delays and agrochemical cyclicality. Net-positive trajectory expected FY26+, positioning stronger competitive standing in specialty chemicals.

Capacity Expansion with Built-in Revenue Visibility Jubilant Ingrevia's agro-intermediate CDMO investment unlocks contracted revenue with predictable scaling. Material dispatch has commenced, enabling Q3/Q4 FY25 revenue recognition. While initial margins face ramp-up pressures (70-75% gross), EBITDA improves significantly post-70% utilization, targeting 15-25% margins in 2-3 quarters. The CDMO model provides client stickiness and operating leverage benefits. Key risks include ramp delays and agrochemical cyclicality. Net-positive trajectory expected FY26+, positioning stronger competitive standing in specialty chemicals.